Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L19-IL2 + dacarbazine
- Development stage
- Phase 2
- Lead developer
- Philogen
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
**L19-IL2 + dacarbazine** is a combination therapy for metastatic melanoma comprising an immunocytokine fusion protein (L19-IL2) and the classic alkylating agent dacarbazine. L19-IL2 consists of an antibody fragment (L19) targeting the EDB domain of fibronectin—a marker of tumor angiogenesis—and human interleukin-2 (IL2). This design delivers IL2 selectively to tumors, promoting local immune stimulation. Dacarbazine is a cytotoxic small molecule with antineoplastic activity. Phase I/II and randomized phase II studies have demonstrated that this combination is tolerable and shows activity (e.g., improved overall response rate and progression-free survival) in advanced or metastatic melanoma[1][2][3][4].
- Brand names
- Dtic-Dome
- Other names
- L19IL2 + dacarbazineL19-IL2 + DTICL19IL2 plus dacarbazineL-19IL2 plus dacarbazineL 19IL2 plus dacarbazine
02
Targets
DNAED-B (Fibronectin extra domain B)IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on L19-IL2 + dacarbazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L19-IL2 + dacarbazine.